Business, energy, technology, markets and global industry news from Business News Today

neuropsychiatry

PharmaDeviceNews neuropsychiatry
Representative image of neuropsychiatry drug research, highlighting Draig Therapeutics’ DT-101 Phase 1 data, AMPA receptor potentiation and the search for new major depressive disorder treatments.
Pharma & Biotech

Draig Therapeutics DT-101 Phase 1 data put MEG biomarkers at the centre of depression trials

DT-101 may revive AMPA receptor depression research, but Phase 2 must prove safety signals can become real clinical benefit.

Read More
Pharma & Biotech

Autobahn’s elunetirom Fast Track win puts bipolar depression back in regulatory focus

Bipolar depression needs better options. Autobahn’s elunetirom Fast Track status raises the stakes for its Phase 2 readout.

Read More
Features & Analysis

How the PharmAla Biotech Holdings Inc. and Jupiter Neurosciences, Inc. deal reflects changing investor expectations in psychedelics

Explore why the PharmAla and Jupiter Neurosciences licensing deal could reshape investor sentiment around next-generation psychedelic therapeutics.

Read More
Representative image: Vistagen’s fasedienol Phase 3 trial highlights the growing search for rapid, as-needed nasal spray treatments for social anxiety disorder, especially in high-pressure public speaking and performance settings.
Pharma & Biotech

Why PALISADE-4 is a high-stakes test for Vistagen’s nose-to-brain anxiety drug strategy

Social anxiety needs faster options. Vistagen’s fasedienol now faces the Phase 3 test that could make or break its nasal-spray thesis.

Read More
Representative image of a clinical consultation on long-term schizophrenia care, as Johnson & Johnson’s CAPLYTA FDA label update sharpens focus on relapse prevention, treatment stability, and durability in neuropsychiatric therapy.
Pharma & Biotech

Johnson & Johnson’s CAPLYTA update raises the bar for long-term schizophrenia stability

Schizophrenia drugs face a durability test. CAPLYTA’s FDA update gives Johnson & Johnson a stronger long-term stability story.

Read More
Pharma & Biotech

What BioXcel Therapeutics’ latest BXCL501 milestone could mean for neuropsychiatric care

Find out how BioXcel Therapeutics’ BXCL501 study could reshape acute stress care and influence future neuropsychiatric treatment pathways.

Read More
Pharma & Biotech

What Alto Neuroscience’s ALTO-101 setback reveals about the difficulty of treating cognitive impairment in schizophrenia

Alto Neuroscience’s ALTO-101 missed in Phase 2. Read what the setback means for schizophrenia cognition, partnering prospects, and ALTO-207 next.

Read More
Pharma & Biotech

Amani Therapeutics bets $25m on expanding clozapine access in schizophrenia

Amani Therapeutics raises $25M to advance AM-01, a fixed-dose clozapine combination targeting neutropenia. Analysis of what changes — and what risks remain.

Read More
Pharma & Biotech

Can TN-001 avoid hallucinogenic pitfalls while delivering rapid antidepressant effects?

Transneural’s TN-001 shows rapid neuroplasticity without hallucinogenic effects. Find out what this could mean for MDD and PTSD treatment strategies.

Read More